Xxonuxxphaxxa LXX Pharmaceutical Import Profile — United States (DGFT 2022–2026)

Name: Xxonuxxphaxxa LXX Pharmaceutical Import Records from India — 2 Products, $400.0K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Xxonuxxphaxxa LXX — Pharmaceutical Importer Profile (2026) | 2 Products, $400.0K Trade | TransData Nexus

Xxonuxxphaxxa LXX

Pharmaceutical Importer · United States · Advanced Antibiotics Focus · $400.0K Total Trade · DGFT Verified

Xxonuxxphaxxa LXX is a pharmaceutical importer based in United States with a total trade value of $400.0K across 2 products in 1 therapeutic categories. Based on 8 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Xxonuxxphaxxa LXX sources from 3 verified Indian suppliers, with Spicejet Limited accounting for 66.7% of imports.

Xxonuxxphaxxa LXX — Import Portfolio & Supplier Network

Xxonuxxphaxxa LXX import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Xxonuxxphaxxa LXX?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Spicejet Limited	$400.0K	8	66.7%
Aurobindo Pharma Limited	$100.0K	2	16.7%
Apl Healthcare Limited	$100.0K	2

What Formulations Does Xxonuxxphaxxa LXX Import?

Formulation	Value	Ships
Sulfamethoxazole / trimethoprim	$200.0K	4
Amoxicillin trihydrate/ clavulanate	$50.0K	1
Betacillin tablets 375 MG (300+75 MG)	$50.0K	1
Amoxicillin trihydrate/clavulanate	$50.0K	1
Amoxicillin and clavulanate	$50.0K	1
Umbrellin oral drops 62.5 MG/ML 15 ML	$50.0K	1
Amoxicillin / clavulanic acid	$50.0K	1
Amoxicillin / clavulanic acid oral	$50.0K	1
Betacillin drops 62.5MG/ML 15ML	$50.0K	1

Xxonuxxphaxxa LXX imports 9 distinct pharmaceutical formulations. Showing top 9 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Sulfamethoxazole	Advanced Antibiotics	$200.0K	4	1.0%	7
2	Trimethoprim	Advanced Antibiotics	$200.0K	4	0.8%	8

Xxonuxxphaxxa LXX imports 2 pharmaceutical products across 1 categories into United States totaling $400.0K.

Xxonuxxphaxxa LXX — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Xxonuxxphaxxa LXX is a United States-based pharmaceutical importer specializing in the acquisition of finished pharmaceutical formulations from international suppliers, particularly from India. The company operates as a buyer, sourcing medications to meet the demands of the U.S. healthcare market. While specific details about its headquarters and parent company are not publicly disclosed, Xxonuxxphaxxa LXX plays a significant role in the U.S. pharmaceutical distribution network by facilitating the importation of essential medications.

2Distribution Network

The distribution network of Xxonuxxphaxxa LXX is not publicly detailed. However, as a pharmaceutical importer, the company likely collaborates with various logistics partners to ensure the efficient and compliant delivery of imported medications across the United States. This would involve adhering to stringent regulatory requirements and maintaining robust supply chain management practices to guarantee timely and secure distribution.

3Industry Role

Xxonuxxphaxxa LXX functions primarily as a pharmaceutical importer, sourcing finished pharmaceutical formulations from international suppliers, notably from India, to supply the U.S. market. By importing medications, the company contributes to the diversification and availability of pharmaceutical products within the United States, supporting the healthcare system's needs.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Xxonuxxphaxxa LXX

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Xxonuxxphaxxa LXX's sourcing strategy exhibits a high degree of concentration, with all its imports originating from three Indian suppliers: SPICEJET LIMITED, AUROBINDO PHARMA LIMITED, and APL HEALTHCARE LIMITED. This concentrated sourcing approach may present risks related to supply chain disruptions, such as production delays or quality control issues. However, it could also indicate strategic partnerships and streamlined procurement processes. The stability of these relationships is crucial for maintaining a consistent supply of medications.

2Supply Chain Resilience

The resilience of Xxonuxxphaxxa LXX's supply chain is closely tied to the reliability of its Indian suppliers. The company's reliance on a limited number of suppliers may expose it to risks if any of these suppliers face operational challenges or regulatory issues. Diversifying the supplier base and establishing contingency plans could enhance supply chain resilience. Ensuring that suppliers comply with international quality standards and have robust manufacturing practices is essential for maintaining the integrity of the supply chain.

3Strategic Implications

Importing Pharmaceuticals into United States — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United States

1Regulatory Authority & Framework

In the United States, the Food and Drug Administration (FDA) serves as the primary regulatory authority overseeing the importation of pharmaceutical products. The FDA enforces regulations to ensure that imported drugs meet safety, efficacy, and quality standards. Key legislation governing pharmaceutical imports includes the Federal Food, Drug, and Cosmetic Act, which outlines requirements for drug approval, labeling, and manufacturing practices. The FDA's Center for Drug Evaluation and Research (CDER) is responsible for evaluating and approving new drugs and ensuring that existing drugs remain safe and effective.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products entering the U.S. include registration with the FDA. Foreign drug establishments that manufacture, repack, re-label, or salvage drug products intended for import into the U.S. must register with the FDA before offering a drug for import and renew annually. Additionally, these establishments must identify a U.S. Agent and include all known importers in their drug registration. Good Manufacturing Practice (GMP) certificates, such as EU GMP, WHO GMP, or PIC/S, are recognized by the FDA and are essential for ensuring that imported drugs meet quality standards. Wholesale distribution authorization is also required to legally distribute pharmaceutical products within the U.S.

Xxonuxxphaxxa LXX — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Xxonuxxphaxxa LXX's focus on importing advanced antibiotics, specifically sulfamethoxazole and trimethoprim, suggests a strategic alignment with market demand for effective antimicrobial therapies. The prevalence of bacterial infections and the need for reliable treatments drive the importation of these medications. By sourcing these products, Xxonuxxphaxxa LXX addresses a critical segment of the U.S. pharmaceutical market, contributing to public health by ensuring the availability of essential antibiotics.

2Sourcing Profile

Xxonuxxphaxxa LXX's sourcing strategy emphasizes the importation of generic antibiotics from India, focusing on finished pharmaceutical formulations. This approach leverages India's established pharmaceutical manufacturing capabilities and cost advantages. By importing finished formulations, Xxonuxxphaxxa LXX can offer ready-to-market products, reducing lead times and meeting the immediate needs of the U.S. healthcare system.

3Market Positioning

Based on its product mix, Xxonuxxphaxxa LXX serves the wholesale distribution segment of the U.S. pharmaceutical market. By importing essential antibiotics, the company supplies these medications to various healthcare providers, including hospitals, clinics, and pharmacies, ensuring that critical treatments are accessible to patients across the country.

Seller's Guide — How to Become a Supplier to Xxonuxxphaxxa LXX

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to enter Xxonuxxphaxxa LXX's supply chain by offering competitive pricing, reliable delivery, and adherence to quality standards. Diversifying the supplier base could enhance Xxonuxxphaxxa LXX's supply chain resilience and reduce dependency on a few suppliers. Additionally, Indian exporters can explore opportunities to supply other therapeutic categories that Xxonuxxphaxxa LXX may consider adding to its portfolio, thereby expanding their market reach.

2Requirements & Qualifications

Indian exporters seeking to supply Xxonuxxphaxxa LXX and the U.S. market must ensure that their manufacturing facilities are registered with the FDA and comply with recognized GMP standards, such as EU GMP, WHO GMP, or PIC/S. Products must meet FDA labeling requirements, including English language labels with necessary information. Additionally, exporters should be prepared to provide documentation such as Certificates of Analysis (COA), Certificates of Pharmaceutical Product (CPP), and Certificates of Origin (COO) to support regulatory compliance and facilitate the import process.

3How to Approach

Frequently Asked Questions — Xxonuxxphaxxa LXX

What products does Xxonuxxphaxxa LXX import from India?

Xxonuxxphaxxa LXX imports 2 pharmaceutical products across 1 categories. Top imports: Sulfamethoxazole ($200.0K), Trimethoprim ($200.0K).

Who supplies pharmaceuticals to Xxonuxxphaxxa LXX from India?

Xxonuxxphaxxa LXX sources from 3 verified Indian suppliers. The primary supplier is Spicejet Limited (66.7% of imports, $400.0K).

What is Xxonuxxphaxxa LXX's total pharmaceutical import value?

Xxonuxxphaxxa LXX's total pharmaceutical import value from India is $400.0K, based on 8 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Xxonuxxphaxxa LXX focus on?

Xxonuxxphaxxa LXX imports across 1 categories. The largest: Advanced Antibiotics (100.0%).

Get Full Xxonuxxphaxxa LXX Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.